Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc.
(“Furiex” or “the Company”) (NasdaqGS: FURX) of claims of breaches of
fiduciary duty and other violations of state law against the board of
directors of the Company in connection with the sale of the Company to
Forest Laboratories, Inc. (“Forest”). A complaint was filed in Delaware
state court.
Click here to learn more about the investigation: http://zlk.9nl.com/furiex-pharmaceuticals-furx,
or call: 877-363-5972. There is no cost or obligation to you.
Under the terms of the transaction, Furiex shareholders will receive
$95.00 per share in cash for each share of Furiex stock they own. The
transaction has a total approximate value of $1.1 billion. An additional
$30.00 per share ($360 million in aggregate) may be payable to
shareholders in a Contingent Value Right (CVR) based on the status of
eluxodoline, Furiex’s lead product, as a controlled drug following
approval. The claims concern whether the Furiex Board of directors
breached their fiduciary duties to stockholders by failing to adequately
shop the Company before agreeing to enter into this transaction, and
whether Forest is underpaying for Furiex shares.
If you own Furiex common stock and wish to obtain additional
information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/furiex-pharmaceuticals-furx.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. For more information, please feel
free to contact any of the attorneys listed below. Attorney advertising.
Prior results do not guarantee similar outcomes.
Copyright Business Wire 2014